IND Indy Diarytech Limited Com

Helix BioPharma Corp. (TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP), a
biopharmaceutical company developing drug candidates for the prevention and
treatment of cancer, today announced that it has filed its complete response to
the "clinical hold" issues previously raised by the United States Food and Drug
Administration ("FDA") related to its pending Topical Interferon Alpha-2b, Phase
II/III, low-grade cervical lesion efficacy trial investigational new drug
("IND") application. Topical Interferon Alpha-2b is the Company's most advanced
product in development incorporating its proprietary Biphasix(TM) drug delivery
technology and is designed to offer a superior means of delivering
interferon-alpha-2b therapeutically to human papillomavirus (HPV) infected
tissues.


"We have endeavoured to address the issues raised by the FDA in a clear and
comprehensive manner," said John Docherty, President of Helix BioPharma Corp.
"We are hopeful that our response will be accepted by the FDA."


The review process typically requires 30 days, during which time the FDA will
decide if an applicant is permitted to proceed with its proposed clinical trial.


Assuming regulatory approval is obtained, the Company will require, among other
things, additional funding as well as strategic partner support before it can
commence the pending U.S. Phase II/III trial.


About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company mainly focused in the field
of cancer therapy. The Company is actively developing innovative products for
the prevention and treatment of cancer based on its proprietary technologies.
Helix's product development initiatives include its Topical Interferon Alpha-2b
and its novel L-DOS47 new drug candidate. Helix is listed on the TSX, NYSE Amex
and FSE under the symbol "HBP". For more information, please visit
www.helixbiopharma.com.


Forward-Looking Statements and Risks and Uncertainties 
This News Release contains forward-looking statements and forward-looking
information (collectively, "forward-looking statements"), within the meaning of
applicable securities laws, regarding the Company's hope that its clinical hold
response will be accepted by the FDA; its plans for a U.S. Phase II/III clinical
trial for Topical Interferon Alpha-2b in patients with low grade cervical
lesions; its need for regulatory approval, strategic support and financing prior
to commencing the clinical trial; the timing of the FDA review process; and the
Company's development of innovative products for the prevention and treatment of
cancer. Although Helix believes that the expectations reflected in such
forward-looking statements are reasonable, such statements involve risks and
uncertainties, and undue reliance should not be placed on such statements.
Certain material factors or assumptions which have been applied in making
forward-looking statements, include, but are not limited to, assumptions
regarding the safety and efficacy of Helix's drug candidates; that the clinical
hold will be removed by the FDA in a timely manner; the timely receipt of
necessary regulatory approvals and appropriate financing and strategic partner
support; and that the Company's drug candidates will ultimately be successfully
developed and commercialized. Important risk factors that could cause actual
results to differ materially from these forward-looking statements include,
without limitation, that the Company's assumptions may prove to be incorrect;
the Company's continuing need for additional capital and for substantial funding
beyond its current resources, as well as strategic partner support, to conduct
the proposed U.S. trial, which are not assured; the risk that the FDA may not
remove the clinical hold on the IND application, either at all or in a timely
manner; the planned clinical trial could fail; uncertainty whether the Company's
drug product candidates will be successfully developed and commercialized; and
the risk of changes in business strategy or development plans. Investors should
consult the Company's quarterly and annual filings, including its latest Form
20-F, with the Canadian and U.S. securities commissions at www.sedar.com and at
www.sec.gov for additional information on these and other risks and
uncertainties which may affect the Company and its product development
initiatives. Investors are cautioned against placing undue reliance on
forward-looking statements. Forward-looking statements are based on the beliefs,
assumptions, opinions and expectations of Helix's management at the time they
are made, and Helix does not assume any obligation to update any forward-looking
statement should those beliefs, assumptions, opinions or expectations change,
except as required by securities law.

Indy Diarytech Limited Com (TSXV:IND)
Historical Stock Chart
From Oct 2024 to Nov 2024

Indy Diarytech Limited Com (TSXV:IND)
Historical Stock Chart
From Nov 2023 to Nov 2024